Location of Repository

Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma

By R.K. (Rutger) Balvers, Z. (Zineb) Belcaid, S.K. (Sanne) van den Hengel, J.J. (Jenneke) Kloezeman, J. (Jeroen) Vrij, H. (Hiroaki) Wakimoto, R.C. (Rob) Hoeben, J.E.M.A. (Reno) Debets, S. (Sieger) Leenstra, C.M.F. (Clemens) Dirven and M.L.M. (Martine) Lamfers


Oncolytic adenoviral vectors are a promising alternative for the treatment of glioblastoma. Recent publications have demonstrated the advantages of shielding viral particles within cellular vehicles (CVs), which can be targeted towards the tumor microenvironment. Here, we studied T-cells, often having a natural capacity to target tumors, for their feasibility as a CV to deliver the oncolytic adenovirus, Delta24-RGD, to glioblastoma. The Jurkat T-cell line was assessed in co-culture with the glioblastoma stem cell (GSC) line, MGG8, for the optimal transfer conditions of Delta24-RGD in vitro. The effect of intraparenchymal and tail vein injections on intratumoral virus distribution and overall survival was addressed in an orthotopic glioma stem cell (GSC)-based xenograft model. Jurkat T-cells were demonstrated to facilitate the amplification and transfer of Delta24-RGD onto GSCs. Delta24-RGD dosing and incubation time were found to influence the migratory ability of T-cells towards GSCs. Injection of Delta24-RGD-loaded T-cells into the brains of GSC-bearing mice led to migration towards the tumor and dispersion of the virus within the tumor core and infiltrative zones. This occurred after injection into the ipsilateral hemisphere, as well as into the non-tumor-bearing hemisphere. We found that T-cell-mediated delivery of Delta24-RGD led to the inhibition of tumor growth compared to non-treated controls, resulting in prolonged survival (p = 0.007). Systemic administration of virus-loaded T-cells resulted in intratumoral viral delivery, albeit at low levels. Based on these findings, we conclude that T-cell-based CVs are a feasible approach to local Delta24-RGD delivery in glioblastoma, although efficient systemic targeting requires further improvement

Topics: Cellular vehicles, Delta24-RGD, Glioblastoma, GSC, Oncolytic, T-cell therapy, Virotherapy
Year: 2014
DOI identifier: 10.3390/v6083080
OAI identifier: oai:repub.eur.nl:82895
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://repub.eur.nl/pub/82895 (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.